A PHARMACOEPIDEMIOLOGICAL STUDY OF NEW DRUG APPROVAL PATTERN OF JAPAN

Nirav Patel; Nilesh  Chavda; JATINKUMAR V DHANANI

doi:10.22159/ajpcr.2024v17i11.52407

Authors

Nirav Patel Department of Pharmacology, GMERS Medical College, Vadodara, Gujarat, India. https://orcid.org/0009-0009-8020-8576
Nilesh Chavda Department of Pharmacology, GMERS Medical College, Valsad, Gujarat, India
JATINKUMAR V DHANANI Department of Pharmacology, GMERS Medical College, Navsari, Gujarat, India. https://orcid.org/0000-0002-2247-5731

DOI:

https://doi.org/10.22159/ajpcr.2024v17i11.52407

Keywords:

New drug development, New drug approval pattern, Japan

Abstract

Objectives: The objective of the study was to study the drug development and drug approval pattern of a developed Asian country: Japan.

Methods: Data available on official website of Japan government health authority was compiled for the duration of January 2017–December 2021. The new approved drugs were classified based on different parameters such as active ingredient, drug approval date, review category, new approval or partial change, Indication of drugs, and WHO anatomic thoracic classification. The descriptive analysis of data was done using LibreOffice Calc.

Results: Out of 545 drugs approved, 46% were anti-neoplastic and immunomodulating agent, 10% were anti-infective and 9% were Nervous system category. Furthermore, among all approved drugs, 51.38% were new approved drugs while 48.62% of drugs were approved with partial change in dosage, route, or indications.

Conclusion: This study showed new drug development and approval was done significantly for anti-cancer agents and agents for non-communicable diseases.

Downloads

Download data is not yet available.

References

New Drugs and Clinical Trials Rules 2019 G.S.R. 227(E) CDSCO; 2019. Available from: https://cdsco.gov.in/opencms/export/sites/ cdsco_web/pdfdocumentsnewdrugs_ctrules_2019.pdf [Last accessed on 2022 May 28].

Clinical Trials Guidance: Clinical Research Materials. GN-IOCTB-03 Rev. No. 002. Health Sciences Authority-health Products Regulation Group, Singapore. Available from: https://www.hsa.gov.sg/docs/ default-source/hprg-io-ctb/hsa_gn-ioctb-03_crm_1mar2021.pdf [Last accessed on 2022 May 28].

Kataria BC, Panchal PJ, Panchasara AK, Pandya AS, Parmar MR. Comparison of new drug approval by regulatory agencies of US, EU and India. Int J Basic Clin Pharmacol. 2016;5:112-5.

Central Drug Standard Control Organisation. Directorate General of Health Services. Ministry of Health and Family Welfare: Government of India. Available from: https://cdsco.gov.in/opencms/opencms/en/ home [Last accessed on 2022 May 28].

Center for Drug Evaluation and Research (CDER): US Food and Drug Administration. Available from: https://www.fda.gov/about-fda/fdaorganization/center-drug-evaluation-and-research-cder [Last accessed on 2022 May 28].

European Medicines Agency. Science Medicines Health. Available from: https://www.ema.europa.eu/en [Last accessed on 2022 May 28].

Batta A, Kalra BS, Khirasaria R. Trends in FDA drug approvals over last 2 decades: An observational study. J Family Med Prim Care. 2020;9:105-14.

Health Science Authority. Singapore. Available from: https://www. hsa.gov.sg/announcements?contenttype=New%20Drug%20Approvals [Last accessed on 2022 May 28].

Chavda N, Patel N, Dhanani JV, Solanky P. A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021. Natl J Physiol Pharm Pharmacol. 2023;13:267-73. doi: 10.5455/ njppp.2023.13.06289202220062022

Mullard A. FDA approvals. Nat Rev Drug Discov. 2022;21:83-8.

Kataria BC, Panchasara AK, Pandya AS, Panchal PJ, Parmar MR. Contemplation on new drug approvals by U.S. FDA, 2011-2015. Int J Basic Clin Pharmacol. 2016;5:55-9.

Mullard A. 2016 FDA drug approvals. Nat Rev Drug Discov. 2017;16:73‐6.

Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of the FDA amendment act with trial registration, publication, and outcome reporting. Trials. 2017;18:333.

Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM. Measuring clinical trial transparency: An empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open. 2017;7:e017917.

Charan J, Dhanani JV, Doshi MS, Reljic T, Tsalatsanis A, Kumar A. Drug approval in India does not match the disease burden: A cross-sectional study. J Pharmacol Pharmacother. 2018;9:6-10.

A PHARMACOEPIDEMIOLOGICAL STUDY OF NEW DRUG APPROVAL PATTERN OF JAPAN

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section